mohamad reza Noori-Daloii; Nazanin Rahimi rad; Saeedeh Kavoosi
Volume 25, Issue 1 , May and June 2018, , Pages 1-11
Abstract
According to the growing developments and improvements of cancer immunotherapies, nowadays, special attention has been paid to the immunotherapies of various types of cancers. Chimeric antigen receptor (CAR) T-cell therapy is one of the T-cell therapies that affects tumor cells, not the normal cells. ...
Read More
According to the growing developments and improvements of cancer immunotherapies, nowadays, special attention has been paid to the immunotherapies of various types of cancers. Chimeric antigen receptor (CAR) T-cell therapy is one of the T-cell therapies that affects tumor cells, not the normal cells. Research conducted over the past decades suggests that CAR T-cell based therapies has revolutionized cancer therapies, and has provided precious achievements in the treatment of hematologic malignancies such as leukemia and lymphoma, and solid tumors including neuroblastoma and glioblastoma. In this review article, structure, function of CAR T- cells, along with some of the antigens that are expressed on the surface of the tumor cells and the CAR T-cells targeting them are presented. Subsequently, several examples of successful therapies with the help of this technology are presented and finally, the safety of these therapies and the challenges and future perspectives are discussed.
Mohammad Reza Noori-Daloii; Nazanin Rahimi rad; Saeedeh Kavoosi
Volume 24, Issue 6 , March and April 2018, , Pages 1-12
Abstract
Chimeric antigen receptor- (CAR-) based immunotherapies (CARs), as one of the newest methods for immunotherapy, have heralded a new era of treating cancer. When the CAR is derived from an antibody, the resultant cell should combine the desirable targeting features of an antibody (e.g. lack of requirement ...
Read More
Chimeric antigen receptor- (CAR-) based immunotherapies (CARs), as one of the newest methods for immunotherapy, have heralded a new era of treating cancer. When the CAR is derived from an antibody, the resultant cell should combine the desirable targeting features of an antibody (e.g. lack of requirement for major histocompatibility complex recognition, ability to recognize self antigens). These potential benefits result in the identification of tumor-sprcific antigens which in turneliminates tumor cells by summoning cytokines and co-stimulatory molecules that kill other tumor cells. This review briefly describes basic CAR structure and function, how their antigenic targets are selected, and the development and advancements of this technology to improve their function intumor micro-environment. Afterwards, several examples of successful treatments with the help of this technology are presented and finally, we take a glance at the side effects of this method.